These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 7585656)

  • 61. Clinical significance of nucleophosmin/B23 and human epidermal growth factor receptor 2/neu expressions in gastric cancers.
    Zhou F; Qiu W; Sun L; Xiang J; Sun X; Sui A; Ding A; Yue L
    APMIS; 2013 Jul; 121(7):582-91. PubMed ID: 23489260
    [TBL] [Abstract][Full Text] [Related]  

  • 62. HER-2/neu receptor gene status in endometrial carcinomas: a tissue microarray study.
    Xu M; Schwartz P; Rutherford T; Azodi M; Santin A; Silasi D; Martel M; Hui P
    Histopathology; 2010 Jan; 56(2):269-73. PubMed ID: 20102407
    [No Abstract]   [Full Text] [Related]  

  • 63. HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas.
    Engelsen IB; Stefansson IM; Beroukhim R; Sellers WR; Meyerson M; Akslen LA; Salvesen HB
    Int J Oncol; 2008 Feb; 32(2):307-16. PubMed ID: 18202752
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Absence of amplification of HER-2/neu (c-erbB-2) gene in Ewing's sarcoma: a real-time polymerase chain reaction method.
    Kim GY; Park JH; Kim YW; Jung WW; Unni KK; Park YK
    Pathol Res Pract; 2004; 200(10):663-7. PubMed ID: 15648603
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Prognostic and predictive value of c-erbB-2 (HER-2/neu) gene amplification in human breast cancer.
    Tsuda H H
    Breast Cancer; 2001; 8(1):38-44. PubMed ID: 11180764
    [TBL] [Abstract][Full Text] [Related]  

  • 66. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study.
    Grushko TA; Filiaci VL; Mundt AJ; Ridderstråle K; Olopade OI; Fleming GF;
    Gynecol Oncol; 2008 Jan; 108(1):3-9. PubMed ID: 17945336
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry.
    Sato-Kuwabara Y; Neves JI; Fregnani JH; Sallum RA; Soares FA
    BMC Cancer; 2009 Jan; 9():6. PubMed ID: 19128465
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Prognosis significance of HER-2/neu overexpression/amplification in Chinese patients with curatively resected gastric cancer after the ToGA clinical trial.
    Zhou F; Li N; Jiang W; Hua Z; Xia L; Wei Q; Wang L
    World J Surg Oncol; 2012 Dec; 10():274. PubMed ID: 23249720
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Overexpression/amplification of HER-2/neu is uncommon in hepatocellular carcinoma.
    Xian ZH; Zhang SH; Cong WM; Wu WQ; Wu MC
    J Clin Pathol; 2005 May; 58(5):500-3. PubMed ID: 15858121
    [TBL] [Abstract][Full Text] [Related]  

  • 70. HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma.
    Brien TP; Odze RD; Sheehan CE; McKenna BJ; Ross JS
    Hum Pathol; 2000 Jan; 31(1):35-9. PubMed ID: 10665910
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The association of HER-2/neu amplification with breast cancer recurrence.
    Carr JA; Havstad S; Zarbo RJ; Divine G; Mackowiak P; Velanovich V
    Arch Surg; 2000 Dec; 135(12):1469-74. PubMed ID: 11115354
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Aromatase, cyclooxygenase 2, HER-2/neu, and p53 as prognostic factors in endometrioid endometrial cancer.
    Jongen VH; Briët JM; de Jong RA; Joppe E; ten Hoor KA; Boezen HM; Evans DB; Hollema H; van der Zee AG; Nijman HW
    Int J Gynecol Cancer; 2009 May; 19(4):670-6. PubMed ID: 19509570
    [TBL] [Abstract][Full Text] [Related]  

  • 73. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group.
    Andrulis IL; Bull SB; Blackstein ME; Sutherland D; Mak C; Sidlofsky S; Pritzker KP; Hartwick RW; Hanna W; Lickley L; Wilkinson R; Qizilbash A; Ambus U; Lipa M; Weizel H; Katz A; Baida M; Mariz S; Stoik G; Dacamara P; Strongitharm D; Geddie W; McCready D
    J Clin Oncol; 1998 Apr; 16(4):1340-9. PubMed ID: 9552035
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Her-2/neu expression in testicular cancer--a retrospective analysis in 57 cases.
    Pfister D; Richter S; Thüer D; Giedl J; Heidenreich A; Klotz T
    Urology; 2010 Nov; 76(5):1266.e6-9. PubMed ID: 21056276
    [TBL] [Abstract][Full Text] [Related]  

  • 75. HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma.
    Pisani AL; Barbuto DA; Chen D; Ramos L; Lagasse LD; Karlan BY
    Obstet Gynecol; 1995 May; 85(5 Pt 1):729-34. PubMed ID: 7724103
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Correlation of HER-2/Neu protein expression and HER2 gene amplification with clinical morphological parameters of nonsmall cell lung cancer.
    Kobyakov DS; Avdalyan AM; Bobrov IP; Bychkova EY; Lazarev AF; Lushnikova EL; Nepomnyashchikh LM
    Bull Exp Biol Med; 2014 Oct; 157(6):789-93. PubMed ID: 25348568
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).
    English DP; Bellone S; Cocco E; Bortolomai I; Pecorelli S; Lopez S; Silasi DA; Schwartz PE; Rutherford T; Santin AD
    Am J Obstet Gynecol; 2013 Nov; 209(5):465.e1-9. PubMed ID: 23891627
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Expression and amplification of HER-2/neu oncogene in uterine carcinosarcomas: a marker for potential molecularly targeted treatment?
    Raspollini MR; Susini T; Amunni G; Paglierani M; Castiglione F; Garbini F; Carriero C; Scarselli G; Taddei GL
    Int J Gynecol Cancer; 2006; 16(1):416-22. PubMed ID: 16445668
    [TBL] [Abstract][Full Text] [Related]  

  • 79. HER-2/neu oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary.
    Ross JS; Yang F; Kallakury BV; Sheehan CE; Ambros RA; Muraca PJ
    Am J Clin Pathol; 1999 Mar; 111(3):311-6. PubMed ID: 10078105
    [TBL] [Abstract][Full Text] [Related]  

  • 80. HER-2/neu oncogene amplification and expression in breast and ovarian cancers.
    Press MF; Jones LA; Godolphin W; Edwards CL; Slamon DJ
    Prog Clin Biol Res; 1990; 354A():209-21. PubMed ID: 1978943
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.